ReviewInternational journal of molecular sciences2022
A New Player in Depression: MiRNAs as Modulators of Altered Synaptic Plasticity.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 29 citations in OpenAlex.
- Epigenetic dysregulation in depression: molecular mechanisms, clinical biomarkers, and therapeutic opportunities.Journal of translational medicine · 2026Review
- Longitudinal Analysis of Peripheral MicroRNA Expression and Depressive Symptom Severity Change in a Community Cohort.Epigenomes · 2026Article
- Alterations of microRNAs across human and mouse limbic brain areas: molecular mechanisms and biological processes involved in major depressive disorder.Neurobiology of stress · 2026Article
- MicroRNA-129-5p in the mPFC is involved in the chronic mild stress-induced depression-like behaviors in rats.Acta pharmacologica Sinica · 2026Article
- Estradiol Reverses Ovariectomy-Induced Small RNA-mRNA Stress Signatures to Restore Neuroendocrine, Synaptic, and Immune Homeostasis in the Hypothalamus.Biomolecules · 2026Article
- MicroRNA-425-3p: A Promising Biomarker and Candidate for Pharmacological Intervention in Neuropsychiatric Disabilities with Relevance to Major Depressive Disorder.Neuropsychiatric disease and treatment · 2026Review
- Nanotechnology-Enhanced MicroRNAs for Improved Diagnosis and Treatment of Major Depressive Disorder: A Comprehensive Review.Molecular neurobiology · 2025Review
- MicroRNA-128-3p as a promising target in neuropsychiatric disorders: From epigenetics to pharmacological intervention.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025Review
- Plasma circulating microRNAs and symptoms of depression: Results from a population-based study.Psychiatry and clinical neurosciences · 2025Article
- Music Therapy in Depression: Exploring Mechanisms and Efficacy in Rat Models.Brain sciences · 2025Review
- Non-pharmacological therapeutic paradigms in stress-induced depression: from novel therapeutic perspective with focus on cell-based strategies.Acta neuropsychiatrica · 2025Review
- MicroRNA signatures in neuroplasticity, neuroinflammation and neurotransmission in association with depression.Journal of physiology and biochemistry · 2025Review
- Advances and Challenges in Depression Marker Research.Neuropsychiatric disease and treatment · 2025Review
- MicroRNAs as Regulators of Neuroinflammation in Major Depressive Disorder.Depression and anxiety · 2025Review
- Recent Advances in the miRNA-Mediated Regulation of Neuronal Differentiation and Death.Neuromolecular medicine · 2024Review
- Clinical Insights into MicroRNAs in Depression: Bridging Molecular Discoveries and Therapeutic Potential.International journal of molecular sciences · 2024Review
- Evaluating the Connection between MicroRNAs and Long Non-Coding RNAs for the Establishment of the Major Depressive Disorder Diagnosis.Biomedicines · 2024Review
- Serum Extracellular Vesicle-Derived hsa-miR-2277-3p and hsa-miR-6813-3p Are Potential Biomarkers for Major Depression: A Preliminary Study.International journal of molecular sciences · 2023Article
- A whole transcriptome profiling analysis for antidepressant mechanism of Xiaoyaosan mediated synapse loss via BDNF/trkB/PI3K signal axis in CUMS rats.BMC complementary medicine and therapies · 2023Article
- The antidepressant actions of ketamine and its enantiomers.Pharmacology & therapeutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Depression is a psychiatric disorder that presents with a persistent depressed mood as the main clinical feature and is accompanied by cognitive impairment. Changes in neuroplasticity and neurogenesis greatly affect depression. Without genetic changes, epigenetic mechanisms have been shown to function by regulating gene expression during the body's adaptation to stress. Studies in recent years have shown that as important regulatory factors in epigenetic mechanisms, microRNAs (miRNAs) play important roles in the development and progression of depression through the regulation of protein expression. Herein, we review the mechanisms of miRNA-mediated neuroplasticity in depression and discus synaptic structural plasticity, synaptic functional plasticity, and neurogenesis. Furthermore, we found that miRNAs regulate neuroplasticity through several signalling pathways to affect cognitive functions. However, these pathways do not work independently. Therefore, we try to identify synergistic correlations between miRNAs and multiple signalling pathways to broaden the potential pathogenesis of depression. In addition, in the future, dual-function miRNAs (protection/injury) are promising candidate biomarkers for the diagnosis of depression, and their regulated genes can potentially be used as target genes for the treatment of depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.